These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. Lee DH Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215 [TBL] [Abstract][Full Text] [Related]
26. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Zhu VW; Klempner SJ; Ou SI Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287 [TBL] [Abstract][Full Text] [Related]
27. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance. Takeuchi S; Yano S Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378 [TBL] [Abstract][Full Text] [Related]
28. Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Karachaliou N; Rosell R; Morales-Espinosa D; Viteri S Expert Rev Anticancer Ther; 2014 Jul; 14(7):807-15. PubMed ID: 24611674 [TBL] [Abstract][Full Text] [Related]
29. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536 [TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755 [TBL] [Abstract][Full Text] [Related]
31. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Shea M; Costa DB; Rangachari D Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497 [TBL] [Abstract][Full Text] [Related]
32. [Treatment of patients with ALK gene rearranged non-small cell lung cancer after resistance to crizotinib]. Jiang T; Zhou C Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):69-74. PubMed ID: 25676398 [TBL] [Abstract][Full Text] [Related]
33. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Ou SH; Soo RA Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839 [TBL] [Abstract][Full Text] [Related]
34. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options. Piotrowska Z; Sequist LV Cancer J; 2015; 21(5):371-7. PubMed ID: 26389761 [TBL] [Abstract][Full Text] [Related]
35. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131 [TBL] [Abstract][Full Text] [Related]